United States - English - NLM (National Library of Medicine)

quality care products llc - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 12.5 mg - for the management of nausea and vomiting, and dizziness associated with motion sickness. meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 25 mg - for the management of nausea and vomiting, and dizziness associated with motion sickness. meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 25 mg - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)] . risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiologic

United States - English - NLM (National Library of Medicine)

a-s medication solutions - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 12.5 mg - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)] . risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiologic

United States - English - NLM (National Library of Medicine)

life line home care services, inc. - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine 25 mg - for the management of nausea and vomiting, and dizziness associated with motion sickness. meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

apotheca inc. - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 25 mg - based on a review of this drug by the national academy of sciences - national research council and/or other information, fda has classified the indications as follows: effective: management of nausea and vomiting, and dizziness associated with motion sickness. final classification of the less than effective indications requires further investigation. meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

unit dose services - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride 25 mg - indications based on a review of this drug by the national academy of sciences – national research council and/or other information, fda has classified the indications as follows: effective: management of nausea and vomiting, and dizziness associated with motion sickness. possibly effective: management of vertigo associated with diseases affecting the vestibular system. final classification of the less than effective indications required further investigation. meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)]. risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiological

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see adverse reactions (6) and description (11)]. risk summary data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. however, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data human data epidemiological

United States - English - NLM (National Library of Medicine)

watson laboratories, inc. - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - tablet - 25 mg - prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. meclizine hcl is contraindicated in individuals who have shown a previous hypersensitivity to it.